A genomic approach to identify molecular pathways associated with chemotherapy resistance

Molecular Cancer Therapeutics

Volumn 7, Issue 10, 2008, Pages 3141-3149

  Riedel, Richard F ^a,b   Porrello, Alessandro ^a   Pontzer, Emily ^a   Chenette, Emily J ^a   Hsu, David S ^a,b   Balakumaran, Bala ^a   Potti, Anil ^a,b   Nevins, Joseph ^a,b   Febbo, Phillip G ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CISPLATIN; CLOFIBRATE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GENISTEIN; INDOMETACIN; IONOMYCIN; MATRIX METALLOPROTEINASE; METHIONINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROCHLORPERAZINE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; RAPAMYCIN; ROFECOXIB; SULINDAC SULFONE; TANESPIMYCIN; THALIDOMIDE; TOPOTECAN; TRICHOSTATIN A; UNINDEXED DRUG; VALPROIC ACID; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; INDOLE DERIVATIVE; MORPHOLINE DERIVATIVE; SULFONAMIDE; TAXOID;

AMINO ACID METABOLISM; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; COMPUTER MODEL; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LUNG CANCER; MOLECULAR GENETICS; MOLECULAR INTERACTION; NEOPLASM; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN TARGETING; CELL DEATH; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; GENETICS; GENOMICS; LUNG TUMOR; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE; TUMOR GENE; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; CHROMONES; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENES, NEOPLASM; GENOMICS; HUMANS; INDOLES; LUNG NEOPLASMS; MORPHOLINES; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; SULFONAMIDES; TAXOIDS;

EID: 55749115981     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0642     Document Type: Article

References (34)

1. Bush JA, Li G. Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer 2002;98:323-30.
2. Desoize B, Jardillier J. Multicellular resistance: a paradigmfor clinical resistance? Crit Rev Oncol Hematol 2000;36:193-207.
3. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stemcell hypothesis. J Clin Pharmacol 2005;45: 872-7.
4. Wulfkuhle J, Espina V, Liotta L, et al. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer 2004;40:2623-32.
5. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300.
6. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
7. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601.
8. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34:267-73.
9. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-66.
10. Dengler WA, Schulte J, Berger DP, et al. Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Anticancer Drugs 1995;6:522-32.
11. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35.
12. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
13. Hsu DS, Balakumaran BS, Acharya CR, et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 2007;25:4350-7.
14. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007;104:13086-91.
15. Di Leo A, Tanner M, Desmedt C, et al. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol 2007;18:997-1003.
16. Funato T, Ishii T, Kambe M, et al. Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells. Cancer Gene Ther 2000;7:495-500.
17. Meyer zu Schwabedissen HE, Grube M, Dreisbach A, et al. Epidermal growth factor-mediated activation of the MAP kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos 2006;34:524-33.
18. Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004;10:7031-42.
19. Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995;11:1217-28.
20. Miyake H, Hanada N, Nakamura H, et al. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998;16:933-43.
21. Han JY, Chung YJ, Park SW, et al. The relationship between cisplatin-induced apoptosis and p53, bcl-2 and bax expression in human lung cancer cells. Korean J Intern Med 1999;14:42-52.
22. KimR, Emi M, Tanabe K, et al. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 2004;101:2491-502.
23. Li J, Viallet J, Haura EB. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol 2008;61: 525-34.
24. Murakami T, Shibuya I, Ise T, et al. Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Int J Cancer 2001;93:869-74.
25. Kosmas C, Tsavaris N, Vadiaka M, et al. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 2001;92:2902-10.
26. Nelli F, Naso G, De Pasquale Ceratti A, et al. Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial. J Chemother 2004;16:392-9.
27. Paz-Ares L, Ross H, O'Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008;98:1608-13.
28. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005;23:8389-95.
29. Fossella FV, DeVore R, Kerr RN, et al.; TAX 320 Non-Small Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-62.
30. Mecham JO, Rowitch D, Wallace CD, et al. The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun 1983;117:429-34.
31. Pavillard V, Nicolaou A, Double JA, et al. Methionine dependence of tumours: a biochemical strategy for optimizing paclitaxel chemosensitivity in vitro. Biochem Pharmacol 2006;71:772-8.
32. Mimeault M, Johansson SL, Vankatraman G, et al. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 2007;6: 967-78.
33. Sims-Mourtada J, Izzo JG, Ajani J, et al. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 2007; 26:5674-9.
34. Bild A, Febbo PG. Application of a priori established gene sets to discover biologically important differential expression in microarray data. Proc Natl Acad Sci U S A 2005;102:15278-9.